Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.28 EUR | -4.90% | -12.09% | -6.57% |
Apr. 10 | Transgene: presents vaccine results at AACR | CF |
Mar. 28 | Transgene CFO Steps Down; Successor Assumes Office | MT |
Business Summary
Transgene has a portfolio of 5 products in clinical development: TG4050, the first individualized therapeutic vaccine based on the myvac® platform, TG4001 a therapeutic vaccine for HPV positive cancers, as well as TG6002, BT-001 and TG6050, three oncolytic viruses based on the Invir.IO® viral backbone. Transgene has several other programs in clinical and pre-clinical development that are based on its core viral vector technology.
Transgene is based in Strasbourg, France, and has additional operations in Lyon and China.
Number of employees: 143
Sales per Business
EUR in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Research and Development Collaboration
100.0
%
| 3 | 100.0 % | 1 | 100.0 % | -62.12% |
Sales per region
EUR in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
France
100.0
%
| 3 | 100.0 % | 1 | 100.0 % | -62.12% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Alessandro Riva
CEO | Chief Executive Officer | 63 | 22-03-30 |
Lucie Larguier
DFI | Director of Finance/CFO | - | 16-03-31 |
Maud Brandely
CTO | Chief Tech/Sci/R&D Officer | 70 | 16-03-16 |
Eric Quéméneur
CTO | Chief Tech/Sci/R&D Officer | 60 | 14-08-31 |
Director/Board Member | 63 | 04-12-06 | |
Christophe Ancel
PRN | Corporate Officer/Principal | 60 | - |
Gaëlle Stadtler
HRO | Human Resources Officer | 40 | 21-01-13 |
John Felitti
LAW | General Counsel | 54 | 16-03-16 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 74 | 13-06-18 | |
Alain Mérieux
BRD | Director/Board Member | 85 | 90-12-31 |
Director/Board Member | 63 | 04-12-06 | |
Benoît Habert
BRD | Director/Board Member | 59 | 99-12-31 |
Alessandro Riva
CEO | Chief Executive Officer | 63 | 22-03-30 |
Director/Board Member | 71 | 16-12-31 | |
Maya Said
BRD | Director/Board Member | 47 | 16-12-31 |
Jean-Yves Blay
BRD | Director/Board Member | 61 | 22-05-24 |
Carol Stuckley
BRD | Director/Board Member | 68 | 23-05-04 |
Sandrine Flory
BRD | Director/Board Member | - | 20-12-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 100,852,742 | 34,746,422 ( 34.45 %) | 303,861 ( 0.3013 %) | 34.45 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
TRANSGENE 0.28% | 286,436 | 0.28% | 352,660 $ |
Company contact information
Transgene SA
400, boulevard Gonthier d'Andernach Parc d'Innovation
67405, Strasbourg
+33 3 88 27 91 00
http://www.transgene.frSector
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-6.57% | 145M | |
-2.26% | 104B | |
+1.41% | 97.42B | |
+0.79% | 22.2B | |
-17.84% | 21.23B | |
-11.11% | 18.33B | |
-42.83% | 16.35B | |
-17.63% | 15.06B | |
+4.55% | 13.98B | |
+32.11% | 11.66B |
- Stock Market
- Equities
- TNG Stock
- Company Transgene